These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 18547481)

  • 1. Safety and tolerability of infliximab therapy: suggestions and criticisms based on wide clinical experience.
    Vultaggio A; Matucci A; Parronchi P; Rossi O; Palandri F; Romagnani S; Maggi E
    Int J Immunopathol Pharmacol; 2008; 21(2):367-74. PubMed ID: 18547481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of infusion reactions during infliximab treatment in patients with arthritis.
    Kapetanovic MC; Larsson L; Truedsson L; Sturfelt G; Saxne T; Geborek P
    Arthritis Res Ther; 2006; 8(4):R131. PubMed ID: 16869978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infliximab for the treatment of psoriasis in the U.K.: 9 years' experience of infusion reactions at a single centre.
    Wee JS; Petrof G; Jackson K; Barker JN; Smith CH
    Br J Dermatol; 2012 Aug; 167(2):411-6. PubMed ID: 22404545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
    Baert F; Noman M; Vermeire S; Van Assche G; D' Haens G; Carbonez A; Rutgeerts P
    N Engl J Med; 2003 Feb; 348(7):601-8. PubMed ID: 12584368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Reactions to infliximab infusions in dermatologic patients: consensus statement and treatment protocol. Working Group of the Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología ].
    Puig Sanz L; Sáez E; Lozano MJ; Bordas X; Carrascosa JM; Gallardo F; Luelmo J; Sánchez-Regaña M; Alsina M; García-Patos V;
    Actas Dermosifiliogr; 2009 Mar; 100(2):103-12. PubMed ID: 19445874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease.
    Han PD; Cohen RD
    Drugs; 2004; 64(16):1767-77. PubMed ID: 15301561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infliximab administered with shortened infusion times in a specialized IBD infusion unit: a prospective cohort study.
    Van Assche G; Vermeire S; Noman M; Amant C; Weyts E; Vleminckx A; Vermeyen MJ; Rutgeerts P
    J Crohns Colitis; 2010 Sep; 4(3):329-33. PubMed ID: 21122522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease.
    Clare DF; Alexander FC; Mike S; Dan G; Allan F; Lisa W; Peter HJ
    Eur J Gastroenterol Hepatol; 2009 Jan; 21(1):71-5. PubMed ID: 19060632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes.
    Suhler EB; Smith JR; Wertheim MS; Lauer AK; Kurz DE; Pickard TD; Rosenbaum JT
    Arch Ophthalmol; 2005 Jul; 123(7):903-12. PubMed ID: 16009830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions.
    Duburque C; Lelong J; Iacob R; Seddik M; Desreumaux P; Fournier C; Wallaert B; Cortot A; Colombel JF
    Aliment Pharmacol Ther; 2006 Sep; 24(5):851-8. PubMed ID: 16918890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions.
    Vultaggio A; Matucci A; Nencini F; Pratesi S; Parronchi P; Rossi O; Romagnani S; Maggi E
    Allergy; 2010 May; 65(5):657-61. PubMed ID: 19951375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus.
    Yamamoto S; Nakase H; Matsuura M; Honzawa Y; Masuda S; Inui K; Chiba T
    J Gastroenterol Hepatol; 2010 May; 25(5):886-91. PubMed ID: 20546441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of ANCA-associated vascularitides].
    Guillevin L; Pagnoux C
    Presse Med; 2007 May; 36(5 Pt 2):922-7. PubMed ID: 17408912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infliximab efficacy and safety against refractory systemic necrotising vasculitides: long-term follow-up of 15 patients.
    Josselin L; Mahr A; Cohen P; Pagnoux C; Guaydier-Souquières G; Hayem G; Job-Deslandre C; Liferman F; Pourrat J; Guillevin L
    Ann Rheum Dis; 2008 Sep; 67(9):1343-6. PubMed ID: 18445626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Infliximab in aggressive and refractory rheumatoid arthritis. A pilot study].
    Caramaschi P; Canestrini S; Biasi D; Carletto A; Scambi C; Scarperi A; Bambara LM
    Recenti Prog Med; 2002 Jan; 93(1):19-24. PubMed ID: 11850995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Infectious risk].
    Calabuig E; Salavert M
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():14-22. PubMed ID: 19080987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial.
    Van Assche G; Vermeire S; Ballet V; Gabriels F; Noman M; D'Haens G; Claessens C; Humblet E; Vande Casteele N; Gils A; Rutgeerts P
    Gut; 2012 Feb; 61(2):229-34. PubMed ID: 21948942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease.
    Tabbara KF; Al-Hemidan AI
    Am J Ophthalmol; 2008 Dec; 146(6):845-50.e1. PubMed ID: 18929351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of recurrent cutaneous abscesses during therapy with infliximab.
    De Simone C; Murri R; Maiorino A; Venier A; Caldarola G
    Clin Ther; 2011 Dec; 33(12):1993-6. PubMed ID: 22088412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, antihistamine pretreatment, and infusion number.
    Wasserman MJ; Weber DA; Guthrie JA; Bykerk VP; Lee P; Keystone EC
    J Rheumatol; 2004 Oct; 31(10):1912-7. PubMed ID: 15468353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.